Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray

Evoke Pharma CEO Dave Gonyer joined Steve Darling from Proactive to share news the company has achieved a significant milestone with the listing of its recently issued U.S. patent related to GIMOTI in the U.S. Food and Drug Administration's publication, commonly known as the "Orange Book."

This development is of great importance as patents listed in the Orange Book cover drugs that the FDA has approved and deemed safe and effective for public use. The patent, titled "Nasal Formulations of Metoclopramide," pertains to a collection of nasal solutions of metoclopramide and outlines its characteristics when formulated.

This newly listed patent in the FDA's Orange Book carries a patent term extending until 2029. Its inclusion adds an additional layer of patent protection for GIMOTI, complementing the three prior patents listed.

This achievement underscores Evoke Pharma's commitment to advancing its innovative metoclopramide nasal spray, GIMOTI, which is designed to provide a treatment option for patients suffering from gastroparesis. The FDA's recognition of the patent's significance reaffirms GIMOTI's potential to address the unmet medical needs of patients.

Furthermore, Gonyer shared insights into the company's recent financial performance, reporting a remarkable 38% increase compared to Q2 2023 and an impressive 88% increase year-over-year in Q3. These positive financial results set the stage for Evoke Pharma's ambitious growth plans for 2024.

As Evoke Pharma continues to make strides in the pharmaceutical industry, its commitment to innovation, patient care, and expanding its patent portfolio positions the company for further success in the years ahead. Investors and stakeholders can look forward to the company's continued growth and contributions to improving patient outcomes.

Contact Details

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com